Johns Hopkins Medicine Johns Hopkins Logo
make a gift
hopkins urology on you tube  twitter urology department at hopkins   facebook urology department at hopkins  blog urology department at hopkins  
                
   
Jun Luo, Ph.D. Jun Luo, Ph.D.
Associate Professor of Urology
Johns Hopkins Medical Institutions

Email:jluo1@jhmi.edu

Dr. Jun Luo is an Assistant Professor of Urology. He received his Ph.D. in Anatomy and Cell Biology in 1999, following his thesis work on the Dunning prostate cancer invasion model with Dr. Mary J.C. Hendrix at the University of Iowa. Dr. Jun Luo went on to conduct a postdoctoral fellowship in Dr. William Isaacs' lab at the James Buchanan Brady Urological Institute at the Johns Hopkins University School of Medicine. From 2000 to 2002 he also worked as a Guest Researcher in Dr. Jeffrey Trent's lab at the National Human Genome Research Institute.

Dr. Jun Luo's has focused on genomic studies of prostate cancer.  His main research interests are:

  1. Discovery, validation, and application of molecular determinants and indicators of prostate cancer progression in various treatment settings.
  2. Genomic research to explain the substantial variation in prostate cancer incidence and mortality rates among different geographic regions and racial/ethnic groups.
  3. Prostate tumor biology.

EDUCATION


1986-1990   B.S. Nanjing University  Zoology
1995-1999   Ph.D. University of Iowa  Anatomy and Cell Biology
1999-2002   Post-doc Johns Hopkins University  Oncogenomics

PUBLICATIONS

  1. Luo J, Sharma N, Seftor E, DeLarco J, Heidger PM, Henrix, MJC, and Lubaroff DM.  Heterogeneous Expression of Invasive and Metastatic Properties in a Prostate Tumor Model.  Pathology Oncology Research 3(4):  264-271, 1997.

  2. Luo J, Lubaroff DM, and Hendrix MJC.  Suppression of Prostate Cancer Invasive Potential and Metalloproteinase Activity by E-cadherin Transfection.  Cancer Research 59(15):  3552-3556, 1999.

  3. Sharma N, Luo J, Kirschmann DA, O’Malley Y, Robbins M, Akporiaye ET, Lubaroff DM, Heidger PM, and Hendrix MJC.  A Novel Immunological Model for the Study of Prostate Cancer.  Cancer Research 59(10):  2271-2276, 1999.

  4. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, and Isaacs WB.  Human Prostate Cancer and Benign Prostatic Hyperplasia:  Molecular Dissection by Gene Expression Profiling.  Cancer Research 61(12):  4683-4688, 2001.

  5. Luo J, Zha S, Gage WR, Dunn TA, Hicks J, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, and De Marzo AM.  a-Methylacyl-CoA Racemase:  A New Molecular Marker for Prostate Cancer.  Cancer Research 62(8): 2220-2226, 2002.

  6. Luo J, Dunn T, Ewing C, Chen Y, Trent J, Isaacs W.  Gene Expression Signature of Benign Prostatic Hyperplasia Revealed by cDNA Microarray Analysis.  Prostate 51(3):  189-200, 2002.

  7. Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM, Epstein JI.  Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy.  American Journal of Surgical Pathology 27(8): 1128-33, 2003.

  8. Luo J, Dunn T, Ewing C, Walsh P, Isaacs W.  Decreased Gene Expression of Steroid 5 alpha-Reductase II in Human Prostate Cancer: Implications for Finasteride Therapy of Prostate Carcinoma.  Prostate 57(2): 134-139, 2003.

  9. Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, De Marzo AM, Isaacs WB. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Research 63(21):7365-76, 2003.

  10. De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, Nelson WG. Human prostate cancer precursors and pathobiology. Urology 62(5 Suppl 1): 55-62, 2003.

  11. Luo J., Isaacs W., Trent J., Duggan D. Looking Beyond Morphology: Cancer Gene Expression Profiling using DNA Microarrays. Cancer Investigation. 21(6):937-9, 2003.

  12. Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs WB, Luo J, De Marzo AM, Nelson WG, Pavlovich CP. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. Journal of Urology 172(4 Pt 1):1501-3, 2004.

  13. Faith DA, Isaacs WB, Morgan JD, Fedor HL, Hicks JL, Mangold LA, Walsh PC, Partin AW, Platz EA, Luo J, DeMarzo AM. Trefoil factor 3 overexpression in prostate carcinoma: prognostic importance using tissue microarrays.  Prostate 61 (3): 215-227, 2004 (co-senior author).

  14. Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, Luo J, De Marzo AM, Isaacs WB.Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 63(4):316-23, 2005.

  15. Schwarze SR, Luo J, Isaacs WB, Jarrard DF.Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 64(1): 67-74, 2005.

  16. Fritzsche F, Dahl E, Pahl S, Burkhardt M, Luo J, Mayordomo E, Gansukh T, Dankof A, Knuechel R, Denkert C, Winzer KJ, Dietel MK, Kristiansen G. Prognostic Relevance of AGR2 Expression in Breast Cancer. Clinical Cancer Research 12(6): 1728-34, 2006.

  17. Dunn T, Chen S, Faith D, Hicks J, Platz E, Chen Y, Ewing C, Sauvageot J, Isaacs W, De Marzo A, Luo J. A Novel Role of Myosin VI in Human Prostate Cancer. American Journal of Pathology. 169(5): 1843-54, 2006.
  18. Wei S, Dunn T, Isaacs W, De Marzo A, Luo J. GOLPH2 and MYO6: Putative Prostate Cancer Markers Localized in the Golgi Apparatus. The Prostate 68(13):1387-9, 2008.

  19. Gurel B, Iwata T, Jenkins R, Lan F, Hicks J, Morgan J, Koh C, Cornish T, Isaacs W, Luo J, De Marzo A. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Modern Pathology 21(9):1156-67, 2008.

  20. Apostolou A, Shen Y, Liang Y, Luo J, Fang S. Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death. Experimental Cell Research 314(13):2454-67, 2008.

  21. Dunn T, Fedor H, Isaacs W, De Marzo A, Luo J. Genome Wide Expression Analysis of Recently Processed Formalin-fixed Paraffin Embedded Human Prostate Tissues. Prostate 69(2):214-8, 2008.

  22. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, Hicks JL, Eisenberger M, Nelson WG, Mostwin JL, De Marzo AM. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 69(6): 603-9, 2009.

  23. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Research 69(1):16-22, 2009.

  24. Cheng Y, Kim JW, Liu W, Dunn TA, Luo J, Loza MJ, Kim ST, Zheng SL, Xu J, Isaacs WB, Chang BL. Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer. Prostate 69(3):327-35, 2009.

  25. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing C,  Eisenberger M, Carducci M,  Nelson W, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs W, Visakorpi T, and Bova GS.  Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer. Nature Medicine, 15(5):559-65, 2009.

  26. Luo J. Explaining hormone-deprivation therapy failure in prostate cancer patients. Expert Review of Endocrinology and Metabolism, 2009, in press.

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS

  • 1999-present               American Association for Cancer Research

AWARDS & HONORS

  • Phyllis and Brian L. Harvey Scholar, 2007

  • David H. Koch Foundation Award, 2006

  • Pathology Young Investigators' Day Award for Excellence in Basic Science Research, Department of Pathology, JHUSOM, 2002
  • Scholar-in-Training Award, American Association for Cancer Research, 2001
  • Young Investigator Award, American Association for Cancer Research, 1998
  • Tung-Yang Wing Award for Superior Achievement, Department of Anatomy and Cell Biology, University of Iowa, 1998

PATENTS

Jun Luo, Rong Hu, Thomas Dunn, William Isaacs, G.S. Bova. Composition and methods for treating and preventing prostate cancer and for detecting androgen receptor variants. JHTT Filing No.: P10305-02 (PCT).

Jun Luo, Rong Hu, Thomas Dunn, William Isaacs. Methods of detecting prostate cancer. U.S. Provisional Application No. 60/959,954 (PCT).

   CONTACT INFORMATION

 

  • Address:
    411 Marburg Building,
    600 N Wolf St.
    The Johns Hopkins Hospital
    Baltimore, MD 21287-2101
  • Office: 443-287-5625
  • Fax: 410-502-9336




© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287